U.S. health officials say AstraZeneca may have skewed vaccine 'efficacy data' with 'outdated information'
In an unusual statement issued after midnight on Tuesday, the National Institute of Allergy and Infectious Diseases said an independent monitoring board overseeing AstraZeneca's U.S. COVID-19 vaccine trial told the NIAID and the drugmaker late Monday "it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial." The NIAID, a unit of the National Institutes of Health, is led by Dr. Anthony Fauci, President Biden's top medical adviser.
AstraZeneca reported early Monday that its vaccine had proved to be 79 percent effective against symptomatic COVID-19 in a large U.S. trial, 100 percent effective against serious illness or hospitalization, and carried no increased risk of blood clots. The results were seen as a shot in the arm for the beleaguered vaccine.
But the Data and Safety Monitoring Board (DSMB) "expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data," the NIAID said. The Food and Drug Administration and Centers for Disease Control and Prevention will ultimately conduct a thorough review of the data before approving AstraZeneca's vaccine for use in the U.S., the agency said, but AstraZeneca should "work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The DSMB's analysis of AstraZeneca's U.S.-based trial was "delayed several times because the board had to ask AstraZeneca for revised reports from those handling trial data on behalf of the company," The New York Times reports, citing a person familiar with the matter.
Friction between a safety monitoring board and a study sponsor is "highly irregular," and the NIAID's post-midnight statement is "so, so troubling," clinical trials expert Dr. Eric Topol told the Times. "I've never seen anything like this." AstraZeneca had yet to respond to the statement early Tuesday.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Long summer days in Iceland's highlands
The Week Recommends While many parts of this volcanic island are barren, there is a 'desolate beauty' to be found in every corner
By The Week UK Published
-
The Democrats: time for wholesale reform?
Talking Point In the 'wreckage' of the election, the party must decide how to rebuild
By The Week UK Published
-
5 deliciously funny cartoons about turkeys
Cartoons Artists take on pardons, executions, and more
By The Week US Published
-
US charges Indian tycoon with bribery, fraud
Speed Read Indian billionaire Gautam Adani has been indicted by US prosecutors for his role in a $265 million scheme to secure solar energy deals
By Peter Weber, The Week US Published
-
Boeing machinists approve contract, end strike
Speed Read The company's largest union approved the new contract offer, ending a seven-week strike
By Peter Weber, The Week US Published
-
US economy still strong in final preelection report
Speed Read It grew at a solid 2.8% annual rate from July through September
By Peter Weber, The Week US Published
-
Boeing machinists reject deal, continue strike
Speed Read The rejection came the same day Boeing reported a $6.2 billion quarterly loss
By Peter Weber, The Week US Published
-
Ports reopen after dockworkers halt strike
Speed Read The 36 ports that closed this week, from Maine to Texas, will start reopening today
By Peter Weber, The Week US Published
-
Empty-nest boomers aren't selling their big homes
Speed Read Most Americans 60 and older do not intend to move, according to a recent survey
By Peter Weber, The Week US Published
-
Brazil accuses Musk of 'disinformation campaign'
Speed Read A Brazilian Supreme Court judge has opened an inquiry into Elon Musk and X
By Rafi Schwartz, The Week US Published
-
Disney board fends off Peltz infiltration bid
Speed Read Disney CEO Bob Iger has defeated activist investor Nelson Peltz in a contentious proxy battle
By Rafi Schwartz, The Week US Published